Abstract

BackgroundKnowledge is limited regarding the impact of previously used biological disease modifying anti-rheumatic drugs (bDMARD) on golimumab drug survival and efficacy in inflammatory joint diseases (IJD).ObjectivesTo explore golimumab drug survival...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call